ArticleInternal medicine (Tokyo, Japan)2026
Two-year Outcomes of Remission Induction Therapy with Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A Case Series.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mepolizumab initiation by day 30 and glucocorticoid exposure in newly diagnosed EGPA: a single-center 30-day landmark cohort study.BMC pulmonary medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mepolizumab, which selectively suppresses Interleukin-5, has been proven to be effective in treating eosinophilic granulomatosis with polyangiitis. However, the medium- to long-term outcomes of mepolizumab initiation in the early remission induction phase remain unclear. We investigated the outcomes up to 104 weeks in 10 patients in whom mepolizumab was initiated early in remission (mean, 14 days after glucocorticoid initiation). We found that the disease activity was promptly suppressed at 4 weeks and remained controlled for up to 104 weeks without relapse or adverse events. Glucocorticoids were discontinued at 104 weeks in 50% of patients, and prednisolone ≤4 mg/day was achieved in 70% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.